Sanofi site to produce asthma inhaler tech

SkyePharma will spend £5 million ($7.8 million) to help build a facility in the U.K. that will manufacture the new Flutiform asthma inhaler tech for Sanofi ($SNY). The treatment recently gained European regulatory approval, according to the Manchester Evening News. Production will take place at Sanofi's Holmes Chapel facility beginning in September. About 260 people work there now, and at least 40 will be initially involved in the production, testing and distribution of the inhaler. Employment will double, however, in subsequent years as demand increases, according to company officials. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.